Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.15.3106 on May 27 2008

Journal of Clinical Oncology, Vol 26, No 19 (July 1), 2008: pp. 3183-3188
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Gorin, N.-C.
Right arrow Articles by Rocha, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorin, N.-C.
Right arrow Articles by Rocha, V.

Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation

Norbert-Claude Gorin, Myriam Labopin, Francesco Frassoni, Noel Milpied, Michel Attal, Didier Blaise, Giovanna Meloni, Anna P. Iori, Mauricette Michallet, Roel Willemze, Eric Deconninck, Jean-Luc Harousseau, Emmanuelle Polge, Vanderson Rocha

From the Department of Hematology, Hôpital Saint Antoine; Acute Leukemia Working Party Registry, European Cooperative Group for Blood and Marrow Transplantation Data and Study Office, Faculté de Médecine St-Antoine Université Pierre et Marie Curie and Institut National de la Santé et de la Recherche Médicale (INSERM) Unit U832; Department of Hematology–Bone Marrow Transplantation (BMT), Hôpital St. Louis, Paris; Centre Hospitalier Universitaire (CHU) Bordeaux Hôpital Haut-Leveque, Pessac; Department of Hematology, Hôpital Purpan CHU, Toulouse; Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli Calmettes, INSERM Unité Medicale de Recherche 599, Marseille; BMT Unit, Hôpital E. Herriot, Lyon; Service d‘Hématologie, Hôpital Jean Minjoz, Besancon; Department of Hematology, Hotel Dieu, Nantes, France; Department of Hematology, Ospedale San Martino, Genova; Dip. Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy; and Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands

Corresponding author: Norbert C. Gorin, MD, Hopital Saint-Antoine and Université Pierre et Marie Curie UPMC, 184 Rue du Faubourg Saint-Antoine, Cedex 12 Paris, France 75571; e-mail: norbert-claude.gorin{at}sat.aphp.fr

Purpose: Patients with acute myelocytic leukemia carrying inversion 16 (inv16) or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities. They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses.

Patients and Methods: From 1990 to 2004, 325 adult patients received transplantations in CR1 (159 patients with inv16 and 166 patients with t(8;21), including 35 and 60 patients, respectively, with additional chromosomal abnormalities). Genoidentical allografts were performed in 64 patients with inv16 and 81 patients with t(8;21), and autografts were performed in 95 patients with inv16 and 85 patients with t(8;21).

Results: In patients with inv16, after allogeneic and autologous transplantation, the 5-year leukemia-free survival (LFS) rates were 59% and 66% (P = .5), the relapse incidence (RI) rates were 27% and 32% (P = .45), and the transplantation-related mortality (TRM) rates were 14% and 2% (P = .003), respectively. Female patients had a lower RI and a higher LFS. Additional chromosomal abnormalities, compared with no additional abnormalities, were associated with lower RI rate (12% v 34%, respectively; P = .01) and higher 5-year LFS rate (78% v 59%, respectively; P = .04). In patients with t(8;21), after allogeneic and autologous transplantation, the 5-year LFS rates were 60% and 66% (P = .69), the RI rates were 15% and 28% (P = .03), and the TRM rates were 24% and 6% (P = .003), respectively. Younger age and a lower WBC count at diagnosis were associated with a lower TRM and a better LFS. The TRM was lower and the RI was higher in patients with autologous transplantations versus allogeneic transplantations.

Conclusion: Both autologous and allogeneic transplantation resulted in similar outcomes.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

published online ahead of print at www.jco.org on May 27, 2008.






About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online